American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices and antigen suppliers are experiencing. To help, there are many other elm species that are more or less resistant to this fungal disease and still…
United Healthcare has recently announced a policy change. Effective January 1, 2023, UHC will no longer cover home- and self-administered subcutaneous allergen immunotherapy. The AAOA, in conjunction with AAOHNS, is working to try to reverse this policy change.
In the meantime, we have developed a template letter you can share with your patients explaining the change and the impact on their immunotherapy, and encouraging them to bring the issue to the HR Director to apply pressure from the buyer’s side.
For those of you who participate with UHC, we recommend you consider a signed consent for the potential out-of-pocket cost to the patient for uncovered services. Additionally, if you receive any updates to this new policy, please share them with us at firstname.lastname@example.org.
Here you can find is a sample of the letter issued by UHC, followed by the patient letter template.